Journal Article

DKFZ-2026-00866

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Protective Human Papillomavirus Type 16/18 Vaccine-Induced Neutralizing Antibody Levels Remain Elusive.

Lehtinen, M. O. A. (First author)DKFZ* ; Eriksson, T. ; Petäjä, T. ; Harjula, K. ; Heikkilä, K. ; Hokkanen, M. ; Butt, J. A.DKFZ* ; Michels, B.DKFZ* ; Sehr, P.DKFZ* ; Müller, M.DKFZ* ; Pimenoff, V. ; Waterboer, T. (Last author)DKFZ*

2026
Oxford University Press Oxford

Abstract: We studied human papillomavirus antibodies in a subset of a cohort comprising 16 988 women who received human papillomavirus (HPV) 16/18 vaccination as adolescents, among whom 50 cervical high-grade squamous cell intraepithelial lesions (HSILs) were diagnosed by 28 years of age. No differences in neutralizing HPV16/18 antibody levels between the HSIL cases and 1:2 matched vaccinated controls with or without persistent cervical HPV infection were observed. As compared with the HPV16/18, cross-neutralizing HPV33 antibody levels were significantly increased in the HSIL cases with concomitant cervical and serum sampling. However, during 16 years of follow-up, protective vaccine-induced, HPV16/18 cross-neutralizing (clade A9/A7 specific) antibody levels remained elusive.

Keyword(s): antibody ; cervical neoplasia ; human papillomavirus ; neutralization ; vaccination

Note: #EA:C230#LA:C230#

---

Contributing Institute(s):

1. Infektionen und Krebsepidemiologie (C230)
2. Tumorvirus-spez. Vakzinierungsstrategie (D335)
3. Chemische Biologie Core Facility (W040)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2026

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---